BRPI0514974A - composto, composição, métodos de tratar ou inibir uma doença ou condição, estados de doença induzidos por radical livre em um mamìfero, dano à junta secundário aos procedimentos artroscópicos ou cirúrgicos em um mamìfero, infertilidade em um mamìfero, de diminuir os nìveis de colesterol, triglicerìdeos, lp(a), ou ldl, de fornecer realce na cognição ou neuroproteção, de contracepção em um mamìfero, e para preparar um composto, e, produto - Google Patents

composto, composição, métodos de tratar ou inibir uma doença ou condição, estados de doença induzidos por radical livre em um mamìfero, dano à junta secundário aos procedimentos artroscópicos ou cirúrgicos em um mamìfero, infertilidade em um mamìfero, de diminuir os nìveis de colesterol, triglicerìdeos, lp(a), ou ldl, de fornecer realce na cognição ou neuroproteção, de contracepção em um mamìfero, e para preparar um composto, e, produto

Info

Publication number
BRPI0514974A
BRPI0514974A BRPI0514974-6A BRPI0514974A BRPI0514974A BR PI0514974 A BRPI0514974 A BR PI0514974A BR PI0514974 A BRPI0514974 A BR PI0514974A BR PI0514974 A BRPI0514974 A BR PI0514974A
Authority
BR
Brazil
Prior art keywords
mammal
compound
methods
composition
neuroprotection
Prior art date
Application number
BRPI0514974-6A
Other languages
English (en)
Inventor
An Thien Vu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0514974A publication Critical patent/BRPI0514974A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)

Abstract

COMPOSTO, COMPOSIçãO, MéTODOS DE TRATAR OU INIBIR UMA DOENçA OU CONDIçãO, ESTADOS DE DOENçA INDUZIDOS POR RADICAL LIVRE, EM UM MAMìFERO, DANO à JUNTA SECUNDáRIO AOS PROCEDIMENTOS ARTROSCóPICOS OU CIRúRGICOS EM UM MAMìFERO, INFERTILIDADE EM UM MAMìFERO, DE DIMINUIR OS NìVEIS DE COLESTEROL, TRIGLICERìDEOS, LP(A), OU LDL, DE FORNECER REALCE NA COGNIçãO OU NEUROPROTEçãO, DE CONTRACEPçãO EM UM MAMìFERO, E PARA PREPARAR UM COMPOSTO, E, PRODUTO Essa invenção fornece compostos de 6H-¢1!benzopirano¢4,3-b!quinolina tendo na fórmula 1: A invenção fornece ainda composições incluindo os compostos, métodos para o uso dos compostos, e os métodos da preparação dos compostos.
BRPI0514974-6A 2004-09-07 2005-09-06 composto, composição, métodos de tratar ou inibir uma doença ou condição, estados de doença induzidos por radical livre em um mamìfero, dano à junta secundário aos procedimentos artroscópicos ou cirúrgicos em um mamìfero, infertilidade em um mamìfero, de diminuir os nìveis de colesterol, triglicerìdeos, lp(a), ou ldl, de fornecer realce na cognição ou neuroproteção, de contracepção em um mamìfero, e para preparar um composto, e, produto BRPI0514974A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60776604P 2004-09-07 2004-09-07
PCT/US2005/031696 WO2006029146A2 (en) 2004-09-07 2005-09-06 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS

Publications (1)

Publication Number Publication Date
BRPI0514974A true BRPI0514974A (pt) 2008-07-01

Family

ID=35677606

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514974-6A BRPI0514974A (pt) 2004-09-07 2005-09-06 composto, composição, métodos de tratar ou inibir uma doença ou condição, estados de doença induzidos por radical livre em um mamìfero, dano à junta secundário aos procedimentos artroscópicos ou cirúrgicos em um mamìfero, infertilidade em um mamìfero, de diminuir os nìveis de colesterol, triglicerìdeos, lp(a), ou ldl, de fornecer realce na cognição ou neuroproteção, de contracepção em um mamìfero, e para preparar um composto, e, produto

Country Status (15)

Country Link
US (1) US7354927B2 (pt)
EP (1) EP1789420A2 (pt)
JP (1) JP2008512458A (pt)
KR (1) KR20070061536A (pt)
CN (1) CN101052641A (pt)
AU (1) AU2005282554A1 (pt)
BR (1) BRPI0514974A (pt)
CA (1) CA2578164A1 (pt)
EC (1) ECSP077302A (pt)
IL (1) IL181514A0 (pt)
MX (1) MX2007002789A (pt)
NO (1) NO20071364L (pt)
RU (1) RU2007106870A (pt)
WO (1) WO2006029146A2 (pt)
ZA (1) ZA200701950B (pt)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202004021947U1 (de) 2003-09-12 2013-05-13 Vessix Vascular, Inc. Auswählbare exzentrische Remodellierung und/oder Ablation von atherosklerotischem Material
MXPA06015270A (es) * 2004-07-01 2007-03-15 Wyeth Corp Compuestos tetraciclicos como ligandos de estrogeno.
US8920414B2 (en) 2004-09-10 2014-12-30 Vessix Vascular, Inc. Tuned RF energy and electrical tissue characterization for selective treatment of target tissues
US8396548B2 (en) 2008-11-14 2013-03-12 Vessix Vascular, Inc. Selective drug delivery in a lumen
US9713730B2 (en) 2004-09-10 2017-07-25 Boston Scientific Scimed, Inc. Apparatus and method for treatment of in-stent restenosis
WO2007002867A1 (en) 2005-06-28 2007-01-04 Cv Therapeutics, Inc. Abca1 elevating compounds
AU2007215131A1 (en) * 2006-02-14 2007-08-23 Wyeth Aqueous pharmaceutical formulations of ERbeta selective ligands
US8019435B2 (en) 2006-05-02 2011-09-13 Boston Scientific Scimed, Inc. Control of arterial smooth muscle tone
ES2407329T3 (es) 2006-10-18 2013-06-12 Vessix Vascular, Inc. Sistema para inducir efectos de temperatura deseables sobre un tejido corporal
AU2007310986B2 (en) 2006-10-18 2013-07-04 Boston Scientific Scimed, Inc. Inducing desirable temperature effects on body tissue
WO2008079139A1 (en) * 2006-12-27 2008-07-03 Cv Therapeutics, Inc. Abca1 elevating compounds
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
WO2008091555A2 (en) 2007-01-22 2008-07-31 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
AU2009314133B2 (en) 2008-11-17 2015-12-10 Vessix Vascular, Inc. Selective accumulation of energy with or without knowledge of tissue topography
CA2795229A1 (en) 2010-04-09 2011-10-13 Vessix Vascular, Inc. Power generating and control apparatus for the treatment of tissue
US9192790B2 (en) 2010-04-14 2015-11-24 Boston Scientific Scimed, Inc. Focused ultrasonic renal denervation
US8473067B2 (en) 2010-06-11 2013-06-25 Boston Scientific Scimed, Inc. Renal denervation and stimulation employing wireless vascular energy transfer arrangement
US9408661B2 (en) 2010-07-30 2016-08-09 Patrick A. Haverkost RF electrodes on multiple flexible wires for renal nerve ablation
US9463062B2 (en) 2010-07-30 2016-10-11 Boston Scientific Scimed, Inc. Cooled conductive balloon RF catheter for renal nerve ablation
US9358365B2 (en) 2010-07-30 2016-06-07 Boston Scientific Scimed, Inc. Precision electrode movement control for renal nerve ablation
US9155589B2 (en) 2010-07-30 2015-10-13 Boston Scientific Scimed, Inc. Sequential activation RF electrode set for renal nerve ablation
US9084609B2 (en) 2010-07-30 2015-07-21 Boston Scientific Scime, Inc. Spiral balloon catheter for renal nerve ablation
US8974451B2 (en) 2010-10-25 2015-03-10 Boston Scientific Scimed, Inc. Renal nerve ablation using conductive fluid jet and RF energy
US9220558B2 (en) 2010-10-27 2015-12-29 Boston Scientific Scimed, Inc. RF renal denervation catheter with multiple independent electrodes
US9028485B2 (en) 2010-11-15 2015-05-12 Boston Scientific Scimed, Inc. Self-expanding cooling electrode for renal nerve ablation
US9089350B2 (en) 2010-11-16 2015-07-28 Boston Scientific Scimed, Inc. Renal denervation catheter with RF electrode and integral contrast dye injection arrangement
US9668811B2 (en) 2010-11-16 2017-06-06 Boston Scientific Scimed, Inc. Minimally invasive access for renal nerve ablation
US9326751B2 (en) 2010-11-17 2016-05-03 Boston Scientific Scimed, Inc. Catheter guidance of external energy for renal denervation
US9060761B2 (en) 2010-11-18 2015-06-23 Boston Scientific Scime, Inc. Catheter-focused magnetic field induced renal nerve ablation
US9023034B2 (en) 2010-11-22 2015-05-05 Boston Scientific Scimed, Inc. Renal ablation electrode with force-activatable conduction apparatus
US9192435B2 (en) 2010-11-22 2015-11-24 Boston Scientific Scimed, Inc. Renal denervation catheter with cooled RF electrode
US20120157993A1 (en) 2010-12-15 2012-06-21 Jenson Mark L Bipolar Off-Wall Electrode Device for Renal Nerve Ablation
US9220561B2 (en) 2011-01-19 2015-12-29 Boston Scientific Scimed, Inc. Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury
WO2013013156A2 (en) 2011-07-20 2013-01-24 Boston Scientific Scimed, Inc. Percutaneous devices and methods to visualize, target and ablate nerves
JP6106669B2 (ja) 2011-07-22 2017-04-05 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． ヘリカル・ガイド内に配置可能な神経調節要素を有する神経調節システム
WO2013055826A1 (en) 2011-10-10 2013-04-18 Boston Scientific Scimed, Inc. Medical devices including ablation electrodes
US9420955B2 (en) 2011-10-11 2016-08-23 Boston Scientific Scimed, Inc. Intravascular temperature monitoring system and method
US10085799B2 (en) 2011-10-11 2018-10-02 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
US9364284B2 (en) 2011-10-12 2016-06-14 Boston Scientific Scimed, Inc. Method of making an off-wall spacer cage
EP2768568B1 (en) 2011-10-18 2020-05-06 Boston Scientific Scimed, Inc. Integrated crossing balloon catheter
WO2013058962A1 (en) 2011-10-18 2013-04-25 Boston Scientific Scimed, Inc. Deflectable medical devices
US8951251B2 (en) 2011-11-08 2015-02-10 Boston Scientific Scimed, Inc. Ostial renal nerve ablation
EP2779929A1 (en) 2011-11-15 2014-09-24 Boston Scientific Scimed, Inc. Device and methods for renal nerve modulation monitoring
US9119632B2 (en) 2011-11-21 2015-09-01 Boston Scientific Scimed, Inc. Deflectable renal nerve ablation catheter
CN102584841B (zh) * 2011-12-16 2014-11-12 浙江工业大学 一种喹啉香豆素衍生物及其制备方法及用途
US9265969B2 (en) 2011-12-21 2016-02-23 Cardiac Pacemakers, Inc. Methods for modulating cell function
US9037259B2 (en) 2011-12-23 2015-05-19 Vessix Vascular, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
CN104135958B (zh) 2011-12-28 2017-05-03 波士顿科学西美德公司 用有聚合物消融元件的新消融导管调变神经的装置和方法
US9050106B2 (en) 2011-12-29 2015-06-09 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
WO2013169927A1 (en) 2012-05-08 2013-11-14 Boston Scientific Scimed, Inc. Renal nerve modulation devices
WO2014032016A1 (en) 2012-08-24 2014-02-27 Boston Scientific Scimed, Inc. Intravascular catheter with a balloon comprising separate microporous regions
EP2895095A2 (en) 2012-09-17 2015-07-22 Boston Scientific Scimed, Inc. Self-positioning electrode system and method for renal nerve modulation
WO2014047454A2 (en) 2012-09-21 2014-03-27 Boston Scientific Scimed, Inc. Self-cooling ultrasound ablation catheter
US10398464B2 (en) 2012-09-21 2019-09-03 Boston Scientific Scimed, Inc. System for nerve modulation and innocuous thermal gradient nerve block
CN104869930B (zh) 2012-10-10 2020-12-25 波士顿科学国际有限公司 肾神经调制装置和方法
US9956033B2 (en) 2013-03-11 2018-05-01 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
WO2014143571A1 (en) 2013-03-11 2014-09-18 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
US9808311B2 (en) 2013-03-13 2017-11-07 Boston Scientific Scimed, Inc. Deflectable medical devices
EP2967734B1 (en) 2013-03-15 2019-05-15 Boston Scientific Scimed, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
JP6139772B2 (ja) 2013-03-15 2017-05-31 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 電極パッドと共に使用するための制御ユニットおよび漏電を推定するための方法
US10265122B2 (en) 2013-03-15 2019-04-23 Boston Scientific Scimed, Inc. Nerve ablation devices and related methods of use
WO2014205388A1 (en) 2013-06-21 2014-12-24 Boston Scientific Scimed, Inc. Renal denervation balloon catheter with ride along electrode support
US10022182B2 (en) 2013-06-21 2018-07-17 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation having rotatable shafts
US9707036B2 (en) 2013-06-25 2017-07-18 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation using localized indifferent electrodes
JP6204579B2 (ja) 2013-07-01 2017-09-27 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 腎神経アブレーション用医療器具
WO2015006480A1 (en) 2013-07-11 2015-01-15 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation
EP3019106A1 (en) 2013-07-11 2016-05-18 Boston Scientific Scimed, Inc. Medical device with stretchable electrode assemblies
EP3049007B1 (en) 2013-07-19 2019-06-12 Boston Scientific Scimed, Inc. Spiral bipolar electrode renal denervation balloon
WO2015013301A1 (en) 2013-07-22 2015-01-29 Boston Scientific Scimed, Inc. Renal nerve ablation catheter having twist balloon
US10342609B2 (en) 2013-07-22 2019-07-09 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
US10722300B2 (en) 2013-08-22 2020-07-28 Boston Scientific Scimed, Inc. Flexible circuit having improved adhesion to a renal nerve modulation balloon
WO2015035047A1 (en) 2013-09-04 2015-03-12 Boston Scientific Scimed, Inc. Radio frequency (rf) balloon catheter having flushing and cooling capability
EP3043733A1 (en) 2013-09-13 2016-07-20 Boston Scientific Scimed, Inc. Ablation balloon with vapor deposited cover layer
US11246654B2 (en) 2013-10-14 2022-02-15 Boston Scientific Scimed, Inc. Flexible renal nerve ablation devices and related methods of use and manufacture
CN105592778B (zh) 2013-10-14 2019-07-23 波士顿科学医学有限公司 高分辨率心脏标测电极阵列导管
US9770606B2 (en) 2013-10-15 2017-09-26 Boston Scientific Scimed, Inc. Ultrasound ablation catheter with cooling infusion and centering basket
JP6259098B2 (ja) 2013-10-15 2018-01-10 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 医療デバイスおよび同医療デバイスを製造する方法
JP6259099B2 (ja) 2013-10-18 2018-01-10 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 可撓性を備える導電性ワイヤを備えるバルーン・カテーテル、並びに関連する使用および製造方法
CN105658163B (zh) 2013-10-25 2020-08-18 波士顿科学国际有限公司 去神经柔性电路中的嵌入式热电偶
US11202671B2 (en) 2014-01-06 2021-12-21 Boston Scientific Scimed, Inc. Tear resistant flex circuit assembly
US9907609B2 (en) 2014-02-04 2018-03-06 Boston Scientific Scimed, Inc. Alternative placement of thermal sensors on bipolar electrode
US11000679B2 (en) 2014-02-04 2021-05-11 Boston Scientific Scimed, Inc. Balloon protection and rewrapping devices and related methods of use
CN105602548B (zh) * 2015-12-19 2018-11-06 江西冠能光电材料有限公司 含呋喃的电致红色发光材料及其制备的有机电致发光器件
CN106977523A (zh) * 2017-03-30 2017-07-25 河南师范大学 具有苯基并四氢吡咯结构的fshr拮抗剂及其制备方法
CN106928243A (zh) * 2017-03-30 2017-07-07 毛阿龙 具有生物活性的苯并哌啶并苯胺基类化合物的制备方法
CN106967076A (zh) * 2017-03-30 2017-07-21 河南师范大学 一种具有6h‑二苯并吡喃结构化合物及其制备方法
MD3820874T2 (ro) * 2018-07-12 2023-05-31 Lilly Co Eli Degradanți selectivi ai receptorului estrogen
CN112225744A (zh) * 2020-08-31 2021-01-15 兰州大学 一种6H-苯并吡喃并[3,4-b]喹啉类化合物及其制备方法和用途

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3518273A (en) 1966-08-03 1970-06-30 Warner Lambert Pharmaceutical Benzopyranquinolinol derivatives and process for their production
US3518258A (en) 1967-05-09 1970-06-30 Warner Lambert Pharmaceutical Pyrano(3,2-i)quinolizine and process for the production
US3493579A (en) 1967-05-29 1970-02-03 Little Inc A 1,4-ethano-5h-(1)benzopyrano (3,4-b)pyridines
US3541100A (en) 1967-12-14 1970-11-17 American Cyanamid Co Benzheteroazolo(2,3-a)isoquinolium salts
US3518272A (en) 1968-02-05 1970-06-30 Warner Lambert Pharmaceutical Tetrahydro benzopyranoquinolines and process for their production
US3600375A (en) 1968-03-25 1971-08-17 Dow Chemical Co Azomethanodioxocins
US3551565A (en) 1968-04-26 1970-12-29 Geigy Chem Corp Pharmaceutical compositions and uses of oxazinoisoquinoline derivatives
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
SU1051092A1 (ru) 1982-07-05 1983-10-30 Ростовский Ордена Трудового Красного Знамени Государственный Университет Им.М.А.Суслова Способ получени тиохиндолинов
GB8500605D0 (en) 1985-01-10 1985-02-13 Secretary Trade Ind Brit Damped spring
JPS63238079A (ja) 1987-03-24 1988-10-04 Masatoshi Yamato キノリン系化合物、その製造法及びその化合物を有効成分とする抗癌剤
JPH0720867B2 (ja) 1987-05-26 1995-03-08 キッセイ薬品工業株式会社 骨粗鬆症治療剤
WO1989002739A1 (en) 1987-10-05 1989-04-06 Pfizer Inc. 4-aminopyridine derivatives
JPH02256667A (ja) 1988-12-27 1990-10-17 Masatoshi Yamato 縮合キノリン系化合物およびその製造方法
US5223506A (en) 1991-06-04 1993-06-29 Glaxo Inc. Cyclic antitumor compounds
WO1994020869A1 (en) 1993-03-12 1994-09-15 Ppg Industries, Inc. Novel benzopyrans
US5428040A (en) 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
WO1996010015A1 (en) 1994-09-28 1996-04-04 Shaman Pharmaceuticals, Inc. Cryptolepine analogs with hypoglycemic activity
WO1996019458A2 (en) * 1994-12-22 1996-06-27 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
DE792292T1 (de) 1995-09-08 1998-09-03 Karo Bio Ab, Huddinge Waisen-rezeptor
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
WO1998045272A1 (en) 1997-04-07 1998-10-15 Latrobe University Topoisomerase inhibitors
US7157568B1 (en) 1997-08-05 2007-01-02 American Home Products Corporation Human estrogen receptor-β
US6110962A (en) 1998-05-12 2000-08-29 American Home Products Corporation 11-aryl-benzo[B]naphtho[2,3-D]furans and 11-aryl-benzo[B]naphtho[2,3-D]thiophenes useful in the treatment of insulin resistance and hyperglycemia
GB9814620D0 (en) 1998-07-06 1998-09-02 Karobio Ab Vasculoprotector
WO2000059897A2 (en) 1999-04-06 2000-10-12 Akzo Nobel N.V. Esters and carbonates of 2-(4-hydroxyphenyl)-6(or 5)-hydroxy-benzothiophene derivatives as selective estrogenic compounds
DK1165184T3 (da) 1999-04-09 2004-04-13 Karobio Ab Estrogenreceptor-beta antagonisme og knoglesygdomme
JP2002542187A (ja) 1999-04-16 2002-12-10 アストラゼネカ・アクチエボラーグ エストロゲン−β受容体リガンド
GB9913649D0 (en) 1999-06-11 1999-08-11 Karobio Ab Estrogen receptor
EP1237546A2 (en) 1999-10-01 2002-09-11 Institute of Molecular and Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
US7214706B2 (en) 2000-03-01 2007-05-08 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds
DE60130748T2 (de) 2000-03-27 2008-07-17 N.V. Organon Nicht-steroidale tetracyclische verbindungen für östrogen-verwandte behandlungen
JP2004510815A (ja) 2000-10-13 2004-04-08 アストラゼネカ・アクチエボラーグ エストロゲン受容体−βリガンド
GB2361642A (en) 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
EP1341765A1 (en) 2000-12-07 2003-09-10 AstraZeneca AB Therapeutic compounds
WO2002046168A1 (en) 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
JP2004524289A (ja) 2000-12-22 2004-08-12 アストラゼネカ・アクチエボラーグ 治療化合物
JP3562481B2 (ja) 2001-04-02 2004-09-08 株式会社村田製作所 射出成形方法および射出成形機
GB2374412A (en) 2001-04-11 2002-10-16 Karobio Ab Hypertension treatment and assay
US6559177B2 (en) 2001-04-19 2003-05-06 Wyeth 5, 11-Dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents
US6589980B2 (en) 2001-05-17 2003-07-08 Wyeth Substituted 10,11-benzo[b]fluoren-10-ones as estrogenic agents
EA007382B1 (ru) 2001-11-19 2006-10-27 Эли Лилли Энд Компани Замещенные бензопираны в качестве селективных агонистов бета-рецептора эстрогена
AU2002353739A1 (en) 2001-11-28 2003-06-10 Astrazeneca Ab Therapeutic compounds
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
US6960607B2 (en) 2001-12-13 2005-11-01 Wyeth Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents
TW200301107A (en) 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
US6903238B2 (en) 2001-12-13 2005-06-07 Wyeth Substituted indenones as estrogenic agents
US6835745B2 (en) 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
US20030158169A1 (en) 2002-01-24 2003-08-21 Wyeth Method of treating hemorrhagic shock or systemic inflammatory response syndrome
US20040002524A1 (en) 2002-06-24 2004-01-01 Richard Chesworth Benzimidazole compounds and their use as estrogen agonists/antagonists
WO2004073610A2 (en) 2003-02-13 2004-09-02 Merck & Co., Inc. Estrogen receptor modulators
ATE457308T1 (de) 2003-04-21 2010-02-15 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
CN100374444C (zh) 2003-04-21 2008-03-12 伊莱利利公司 作为选择性β-雌激素受体激动剂的取代的苯并吡喃化合物
DE10318896A1 (de) 2003-04-22 2004-11-25 Schering Ag 8beta-Vinyl-11beta-(omega-substituierte)alkyl-estra-1,3,5(10)-triene
US7279600B2 (en) 2003-05-02 2007-10-09 Wyeth Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents
CL2004000985A1 (es) 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
US7250440B2 (en) 2003-08-12 2007-07-31 Wyeth (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents
AU2004292555A1 (en) 2003-11-24 2005-06-09 Merck & Co., Inc. Estrogen receptor modulators
US7157492B2 (en) 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
AU2005254949A1 (en) 2004-06-10 2005-12-29 Merck & Co., Inc. Estrogen receptor modulators

Also Published As

Publication number Publication date
RU2007106870A (ru) 2008-10-20
JP2008512458A (ja) 2008-04-24
CA2578164A1 (en) 2006-03-16
US7354927B2 (en) 2008-04-08
IL181514A0 (en) 2007-07-04
NO20071364L (no) 2007-04-30
CN101052641A (zh) 2007-10-10
US20060052410A1 (en) 2006-03-09
MX2007002789A (es) 2007-04-24
WO2006029146A3 (en) 2006-04-27
ZA200701950B (en) 2009-11-25
EP1789420A2 (en) 2007-05-30
WO2006029146A2 (en) 2006-03-16
AU2005282554A1 (en) 2006-03-16
KR20070061536A (ko) 2007-06-13
ECSP077302A (es) 2007-04-26

Similar Documents

Publication Publication Date Title
BR0009651A (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas
WO2006052555A8 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
BR0112364A (pt) Combinações de bisfosfonatos, agentes estrogênicos e opcionalmente estrogênios
TR200100768T2 (tr) Cetp önleyicileri olarak 4-karboksiamino-2-ikame edilmiş-1,2,3,4- tetrahidrokinolinler
BR0206955A (pt) Ligantes de receptores de canabinóides
BRPI0407454A (pt) Pirazóis e métodos de preparar e usar os mesmos
IS2313B (is) 1,3-díhýdró-2H-indól-2-ón afleiður og notkun þeirra sem bindlar fyrir V1b eða V1b og V1a arginín-þvagtemprandi viðtaka
NO20000242D0 (no) Tricykliske vasopressin agonister
BR0113989A (pt) Compostos, composições farmacêuticas, processo para a preparação de uma composição farmacêutica, e, uso de pelo menos um dos compostos
UA70960C2 (uk) 4-амінозаміщені-2-заміщені-1,2,3,4-тетрагідрохіноліни як інгібітори протеїну, який переносить холестериловий етер
BRPI0511327A (pt) combinações de glicopirrolato e agonistas do adrenorreceptor beta2
BR9916564A (pt) Combinações para indicações cardiovasculares
EP2332527A3 (en) Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases
BR9811099A (pt) Inibidores de urocinase
AR014261A1 (es) Compuestos hipolipidemicos de benzotiazepina, composiciones y proceso para su preparacion
WO2008076243A3 (en) Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
BRPI0520812A2 (pt) método para preparar um composto de quinolina 4-substituìda, e, composto
Kumar et al. Novel thiocoumarins as inhibitors of TNF-α induced ICAM-1 expression on human umbilical vein endothelial cells (HUVECs) and microsomal lipid peroxidation
BRPI0515499A (pt) derivados de piridina para a inibição de estearoil-coa-desaturase humana
Ruiz et al. Kaempferol inhibits apoptosis in vascular smooth muscle induced by a component of oxidized LDL
BRPI0512783A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos de tratar ou inibir osteoporose ou inibir a desmineralização óssea em um mamìfero, de tratar ou inibir doenças em um mamìfero, de diminuir o colesterol, triglicerìdeos, nìveis de lp (a) ou ldl ou inibir dano vascular em um mamìfero, de prover aumento da cognição ou neuroproteção, de tratar ou inibir estados doentios induzidos por radical livre em um mamìfero, de tratar ou inibir sintomas vasomotores em um mamìfero, de contracepção em um mamìfero, de tratar ou inibir dano de junta secundário a procedimentos artroscópicos ou cirúrgicos em um mamìfero e de tratar ou inibir fertilidade em um mamìfero, composição farmacêutica, e, processo para a preparação de um composto
BR0112365A (pt) Combinações de estatinas, agentes estrogênicos e opcionalmente estrogênios
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
BRPI0607555A2 (pt) inibidores da proteìna microssomal de transferência de triglicirideo e secreção de apo-b
BR0005616A (pt) 2-(3,5-bis-trifluormetil-fenil)-n-metil-n-(6-morfolin-4-i l-4-o-tolil-piridin-3-il)-isobutiramida

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2166 DE 10/07/2012.